Int J Biometeorol:水疗治疗斑块型银屑病真的有效吗?

2022-07-23 医路坦克 MedSci原创

银屑病是一种慢性炎症性皮肤病,本研究评估至少1年以来斑块型银屑病患者进行为期3周的皮肤科水疗法的早期和长期效益。

银屑病是一种慢性炎症性皮肤病,影响一般人群的2-3%。由于其长期性,该疾病具有挑战性,并对生活质量(QoL)和高发病率的共病有负面影响。近年来,几种治疗方法的进步改善了中重度银屑病的治疗,但其中一些治疗方法可能有副作用。对于一个病人,可能需要使用几种不同的治疗方法。此外,在占银屑病人群大多数的病情较轻的患者中,外用药物是一线治疗方法,但对患者而言,使用药物可能会带来负担或困难,而且可能会导致临床依从性较差。

研究表明,医学水对几种慢性病理(如骨关节炎和纤维肌痛)具有临床益处,但很少有研究评估在温泉环境中进行的特定疾病导向的水疗法。

在法国和其他欧洲温泉疗养胜地进行的水疗是一种复杂的治疗干预,将天然热矿泉水浴(水疗按摩浴、身体喷射淋浴、水灌注按摩,有时使用富含矿物质的泥浆)与物理治疗(如在温水矿泉池中监督集体锻炼)、健康护理、放松和患者教育(有时组织在特定的项目中)相结合。

我们的目的是进行一项多中心、对照、平行、开放标签的随机试验,以评估至少1年以来斑块型银屑病患者为期3周的皮肤科温泉疗法的早期和长期效益。我们关注的是生活质量,但也观察了其他标准,如疼痛、瘙痒和银屑病的严重程度。

这项多中心、开放标签、随机试验比较了水疗与常规治疗对照组,直到4.5个月后进行研究评估。法国的五个温泉度假村都提出了Spa治疗方案。入选标准为成人斑块型银屑病患者,皮肤病学生活质量指数(DLQI) > 10,近6个月就诊稳定。主要目标是纳入4.5个月后DLQI≤10。VQ-Dermato和EQ5D-3L还评估了生活质量(QoL)、感知压力量表(PSS)和视觉模拟量表(VAS)疼痛和瘙痒。在2015年1月至2018年11月期间,128名患者被随机分为立即spa治疗(64名)(中位34天内)或常规治疗(61名),直到4.5个月评估。其中,71.2%的人是首次使用spa。

平均DLQI和银屑病面积和严重程度指数分别为16.7和10.5。即时spa治疗组患者达到了主要目标(66.1% [95% CI 52.6% > 77.9%],而对照组患者达到了41.4% [95% CI 28.6% > 55.1%] (p = 0.007)。VQ-Dermato评分和瘙痒VAS评分明显改善。即时水疗治疗组12个月随访结果显示DLQI、vq -皮肤和瘙痒持续改善。

纳入研究时患者的主要特点

主要和次要终点

干预(即时spa治疗)组的长期评估

 

这项随机对照试验表明,水疗治疗可在短期和长期内改善银屑病的生活质量,缓解银屑病的某些症状。

文献来源:Beylot-Barry M,  Mahé E,  Rolland C, Evaluation of the benefit of thermal spa therapy in plaque psoriasis: the PSOTHERMES randomized clinical trial.Int J Biometeorol 2022 Jun;66(6) 

 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1897040, encodeId=b80f189e040bf, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Sat Mar 04 16:43:13 CST 2023, time=2023-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1919471, encodeId=c95f19194e1c2, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sun Jun 11 09:43:13 CST 2023, time=2023-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1330245, encodeId=608c133024522, content=<a href='/topic/show?id=a91c5e92328' target=_blank style='color:#2F92EE;'>#斑块#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57923, encryptionId=a91c5e92328, topicName=斑块)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/4E6244DB7C1860858424437821E08291/100, createdBy=a6a52500039, createdName=ms3994565386320060, createdTime=Thu Jul 21 15:43:13 CST 2022, time=2022-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1490395, encodeId=1ee5149039573, content=<a href='/topic/show?id=f7e85e929c0' target=_blank style='color:#2F92EE;'>#斑块型银屑病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57929, encryptionId=f7e85e929c0, topicName=斑块型银屑病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=435a8732843, createdName=zz73, createdTime=Thu Jul 21 15:43:13 CST 2022, time=2022-07-21, status=1, ipAttribution=)]
    2023-03-04 一闲
  2. [GetPortalCommentsPageByObjectIdResponse(id=1897040, encodeId=b80f189e040bf, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Sat Mar 04 16:43:13 CST 2023, time=2023-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1919471, encodeId=c95f19194e1c2, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sun Jun 11 09:43:13 CST 2023, time=2023-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1330245, encodeId=608c133024522, content=<a href='/topic/show?id=a91c5e92328' target=_blank style='color:#2F92EE;'>#斑块#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57923, encryptionId=a91c5e92328, topicName=斑块)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/4E6244DB7C1860858424437821E08291/100, createdBy=a6a52500039, createdName=ms3994565386320060, createdTime=Thu Jul 21 15:43:13 CST 2022, time=2022-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1490395, encodeId=1ee5149039573, content=<a href='/topic/show?id=f7e85e929c0' target=_blank style='color:#2F92EE;'>#斑块型银屑病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57929, encryptionId=f7e85e929c0, topicName=斑块型银屑病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=435a8732843, createdName=zz73, createdTime=Thu Jul 21 15:43:13 CST 2022, time=2022-07-21, status=1, ipAttribution=)]
    2023-06-11 sunylz
  3. [GetPortalCommentsPageByObjectIdResponse(id=1897040, encodeId=b80f189e040bf, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Sat Mar 04 16:43:13 CST 2023, time=2023-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1919471, encodeId=c95f19194e1c2, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sun Jun 11 09:43:13 CST 2023, time=2023-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1330245, encodeId=608c133024522, content=<a href='/topic/show?id=a91c5e92328' target=_blank style='color:#2F92EE;'>#斑块#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57923, encryptionId=a91c5e92328, topicName=斑块)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/4E6244DB7C1860858424437821E08291/100, createdBy=a6a52500039, createdName=ms3994565386320060, createdTime=Thu Jul 21 15:43:13 CST 2022, time=2022-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1490395, encodeId=1ee5149039573, content=<a href='/topic/show?id=f7e85e929c0' target=_blank style='color:#2F92EE;'>#斑块型银屑病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57929, encryptionId=f7e85e929c0, topicName=斑块型银屑病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=435a8732843, createdName=zz73, createdTime=Thu Jul 21 15:43:13 CST 2022, time=2022-07-21, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1897040, encodeId=b80f189e040bf, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Sat Mar 04 16:43:13 CST 2023, time=2023-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1919471, encodeId=c95f19194e1c2, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sun Jun 11 09:43:13 CST 2023, time=2023-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1330245, encodeId=608c133024522, content=<a href='/topic/show?id=a91c5e92328' target=_blank style='color:#2F92EE;'>#斑块#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57923, encryptionId=a91c5e92328, topicName=斑块)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/4E6244DB7C1860858424437821E08291/100, createdBy=a6a52500039, createdName=ms3994565386320060, createdTime=Thu Jul 21 15:43:13 CST 2022, time=2022-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1490395, encodeId=1ee5149039573, content=<a href='/topic/show?id=f7e85e929c0' target=_blank style='color:#2F92EE;'>#斑块型银屑病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57929, encryptionId=f7e85e929c0, topicName=斑块型银屑病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=435a8732843, createdName=zz73, createdTime=Thu Jul 21 15:43:13 CST 2022, time=2022-07-21, status=1, ipAttribution=)]

相关资讯

JEADV:1例斑块型银屑病患者在接种新冠疫苗后出现泛发性脓疱性银屑病红斑,并用risankizumab成功治疗

随着新冠肺炎疫苗的广泛使用,出现了几种皮肤不良反应,包括先前存在的皮肤病:1例斑块型银屑病患者在接种新冠疫苗后出现泛发性脓疱性银屑病红斑,并用risankizumab成功治疗

BMS口服TYK2抑制剂deucravacitinib治疗斑块型银屑病3期临床成功! 效果优于apremilast

百时美施贵宝(BMS)近日宣布,评估新型抗炎药deucravacitinib(BMS-986165)治疗银屑病的关键3期研究POETYK PSO-1达到了共同主要终点和多个关键次要终点。deucrav

ADV:在斑块型银屑病儿童患者中甲氨蝶呤有效性,不良事件和叶酸方案的研究

在儿科银屑病中,很少有研究评估甲氨蝶呤的有效性、不良事件和叶酸方案。因此,本研究前瞻性地评估了甲氨蝶呤在现实环境中对儿童银屑病患者的不良事件和有效性。

Lancet:IL-17A/F纳米体索洛奇单抗治疗斑块型银屑病II期临床获得成功

索洛奇单抗30-120mg剂量均表现出良好的中重度斑块型银屑病治疗效果,其具有起效快速,改善持久,以及较好安全性的特点

Front Cell Dev:银屑病患者外周血不变性自然杀伤T细胞调节异常

银屑病是一种常见的免疫介导的皮肤病,涉及T细胞介导的免疫,本文探讨了银屑病患者外周血NKT细胞的表达及Suckinumab对其的影响。

JEADV:COVID疫苗诱导的既往斑块型银屑病患者中的脓疱性银屑病

根据以上病例,我们认为值得注意的是,疫苗可能诱发掌跖银屑病,而不仅仅是加剧斑块状银屑病。